HC Wainwright Has Positive Opinion of CRSP FY2026 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a note issued to investors on Tuesday, November 3rd. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($4.49) per share for the year, up from their prior forecast of ($4.53). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($4.44) per share. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q4 2026 earnings at ($1.12) EPS, Q1 2027 earnings at ($1.26) EPS, Q2 2027 earnings at ($1.18) EPS, Q3 2027 earnings at ($1.28) EPS, Q4 2027 earnings at ($1.23) EPS and FY2027 earnings at ($4.95) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, November 2nd. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.09). CRISPR Therapeutics had a negative return on equity of 25.59% and a negative net margin of 1,812.07%. The firm had revenue of $12.67 million for the quarter, compared to the consensus estimate of $14.75 million. The business’s revenue for the quarter was up 1311.1% on a year-over-year basis.

Several other brokerages also recently commented on CRSP. Wells Fargo & Company decreased their price objective on shares of CRISPR Therapeutics from $75.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Wednesday. The Goldman Sachs Group reiterated a “neutral” rating and issued a $55.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. Wall Street Zen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Thursday, October 15th. Finally, Needham & Company LLC restated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $69.69.

CRISPR Therapeutics Stock Performance

CRSP opened at $51.78 on Thursday. The company has a 50 day simple moving average of $53.67 and a two-hundred day simple moving average of $52.84. The company has a debt-to-equity ratio of 0.36, a current ratio of 16.21 and a quick ratio of 17.85. The firm has a market cap of $5.01 billion, a P/E ratio of -10.92 and a beta of 1.92. CRISPR Therapeutics has a 1-year low of $44.12 and a 1-year high of $63.45.

Institutional Trading of CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the stock. Swiss National Bank increased its position in CRISPR Therapeutics by 5.1% in the first quarter. Swiss National Bank now owns 169,700 shares of the company’s stock worth $8,073,000 after purchasing an additional 8,200 shares during the last quarter. Affinity Asset Advisors LLC purchased a new stake in CRISPR Therapeutics during the first quarter valued at $7,136,000. KBC Group NV lifted its position in CRISPR Therapeutics by 3,999.9% during the first quarter. KBC Group NV now owns 116,847 shares of the company’s stock valued at $5,558,000 after purchasing an additional 113,997 shares during the last quarter. Congress Asset Management Co. lifted its position in CRISPR Therapeutics by 1.6% during the third quarter. Congress Asset Management Co. now owns 111,230 shares of the company’s stock valued at $6,153,000 after purchasing an additional 1,777 shares during the last quarter. Finally, California State Teachers Retirement System lifted its position in CRISPR Therapeutics by 29.6% during the first quarter. California State Teachers Retirement System now owns 101,232 shares of the company’s stock valued at $4,816,000 after purchasing an additional 23,109 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Activity at CRISPR Therapeutics

In related news, Director Simeon George sold 14,514 shares of the company’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $49.63, for a total transaction of $720,329.82. Following the completion of the transaction, the director owned 15,486 shares in the company, valued at approximately $768,570.18. This represents a 48.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ali Behbahani sold 13,679 shares of the firm’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $57.09, for a total transaction of $780,934.11. Following the transaction, the director directly owned 16,637 shares of the company’s stock, valued at $949,806.33. The trade was a 45.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 93,558 shares of company stock worth $4,881,663. 5.20% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics News Roundup

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Citigroup raised its price target to $90 from $88 and reaffirmed a “buy” rating, signaling significant potential upside in the analyst’s view. Citigroup price target report
• Positive Sentiment: The company said it will present Phase 1/2 clinical data for zugo-cel, its investigational gene-edited CAR T therapy for relapsed or refractory large B-cell lymphoma, at the ASH meeting in December. The presentation could provide investors with a meaningful pipeline update. Zugo-cel clinical data announcement
• Neutral Sentiment: CRISPR Therapeutics appointed Siva Sakhamuri as chief technical officer. His experience in manufacturing, gene editing and commercial launches may support the company’s operations, though the appointment’s financial impact is not yet clear. Chief technical officer appointment
• Negative Sentiment: Third-quarter results fell short of expectations: the company reported a $1.15-per-share loss versus the $1.06 loss analysts expected, and revenue of $12.67 million versus a $14.75 million consensus estimate. Growing Casgevy use and sales offer a counterpoint, but the earnings shortfall may weigh on sentiment. Third-quarter results coverage
• Negative Sentiment: Brookline Capital Markets slightly lowered its projected earnings per share for 2028, 2029 and 2030, a modestly cautious revision to its long-term outlook.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.